1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Global Antipsychotic Drugs Market- Introduction
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 Global Antipsychotic Drugs Market Landscape
5.1 Historical and Current Market Trends (2018-2023)
5.2 Market Forecast (2024-2032)
6 Global Antipsychotic Drugs Market- Breakup by Therapeutic Class
6.1 First Generation
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2018-2023)
6.1.3 Market Segmentation
6.1.3.1 Haldol
6.1.3.2 Navane
6.1.3.3 Others
6.1.4 Market Forecast (2024-2032)
6.2 Second Generation
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2018-2023)
6.2.3 Market Segmentation
6.2.3.1 Invega
6.2.3.2 Latuda
6.2.3.3 Seroquel
6.2.3.4 Risperdal
6.2.3.5 Zyprexa
6.2.3.6 Geodon
6.2.3.7 Others
6.2.4 Market Forecast (2024-2032)
6.3 Third Generation
6.3.1 Overview
6.3.2 Historical and Current Market Trends (2018-2023)
6.3.3 Market Segmentation
6.3.3.1 Abilify
6.3.4 Market Forecast (2024-2032)
6.4 Attractive Investment Proposition by Therapeutic Class
7 Global Antipsychotic Drugs Market - Breakup by Application
7.1 Schizophrenia
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2018-2023)
7.1.3 Market Segmentation
7.1.4 Market Forecast (2024-2032)
7.2 Bipolar Disorder
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2018-2023)
7.2.3 Market Segmentation
7.2.4 Market Forecast (2024-2032)
7.3 Unipolar Depression
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2018-2023)
7.3.3 Market Segmentation
7.3.4 Market Forecast (2024-2032)
7.4 Dementia
7.4.1 Overview
7.4.2 Historical and Current Market Trends (2018-2023)
7.4.3 Market Segmentation
7.4.4 Market Forecast (2024-2032)
7.5 Others
7.5.1 Historical and Current Market Trends (2018-2023)
7.5.2 Market Forecast (2024-2032)
7.6 Attractive Investment Proposition by Application
8 Global Antipsychotic Drugs Market- Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2018-2023)
8.1.3 Market Segmentation
8.1.4 Market Forecast (2024-2032)
8.2 Retail Pharmacies
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2018-2023)
8.2.3 Market Segmentation
8.2.4 Market Forecast (2024-2032)
8.3 Online Pharmacies
8.3.1 Overview
8.3.2 Historical and Current Market Trends (2018-2023)
8.3.3 Market Segmentation
8.3.4 Market Forecast (2024-2032)
8.4 Attractive Investment Proposition by Distribution Channel
9 Global Antipsychotic Drugs Market– Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Drivers
9.1.1.2 Historical and Current Market Trends (2018-2023)
9.1.1.3 Market Breakup by Therapeutic Class
9.1.1.4 Market Breakup by Application
9.1.1.5 Market Breakup by Distribution Channel
9.1.1.6 Key Players
9.1.1.7 Market Forecast (2024-2032)
9.1.2 Canada
9.1.2.1 Market Drivers
9.1.2.2 Historical and Current Market Trends (2018-2023)
9.1.2.3 Market Breakup by Therapeutic Class
9.1.2.4 Market Breakup by Application
9.1.2.5 Market Breakup by Distribution Channel
9.1.2.6 Key Players
9.1.2.7 Market Forecast (2024-2032)
9.2 Europe
9.2.1 Germany
9.2.1.1 Market Drivers
9.2.1.2 Historical and Current Market Trends (2018-2023)
9.2.1.3 Market Breakup by Therapeutic Class
9.2.1.4 Market Breakup by Application
9.2.1.5 Market Breakup by Distribution Channel
9.2.1.6 Key Players
9.2.1.7 Market Forecast (2024-2032)
9.2.2 France
9.2.2.1 Market Drivers
9.2.2.2 Historical and Current Market Trends (2018-2023)
9.2.2.3 Market Breakup by Therapeutic Class
9.2.2.4 Market Breakup by Application
9.2.2.5 Market Breakup by Distribution Channel
9.2.2.6 Key Players
9.2.2.7 Market Forecast (2024-2032)
9.2.3 United Kingdom
9.2.3.1 Market Drivers
9.2.3.2 Historical and Current Market Trends (2018-2023)
9.2.3.3 Market Breakup by Therapeutic Class
9.2.3.4 Market Breakup by Application
9.2.3.5 Market Breakup by Distribution Channel
9.2.3.6 Key Players
9.2.3.7 Market Forecast (2024-2032)
9.2.4 Italy
9.2.4.1 Market Drivers
9.2.4.2 Historical and Current Market Trends (2018-2023)
9.2.4.3 Market Breakup by Therapeutic Class
9.2.4.4 Market Breakup by Application
9.2.4.5 Market Breakup by Distribution Channel
9.2.4.6 Key Players
9.2.4.7 Market Forecast (2024-2032)
9.2.5 Spain
9.2.5.1 Market Drivers
9.2.5.2 Historical and Current Market Trends (2018-2023)
9.2.5.3 Market Breakup by Therapeutic Class
9.2.5.4 Market Breakup by Application
9.2.5.5 Market Breakup by Distribution Channel
9.2.5.6 Key Players
9.2.5.7 Market Forecast (2024-2032)
9.2.6 Others
9.2.6.1 Historical and Current Market Trends (2018-2023)
9.2.6.2 Market Forecast (2024-2032)
9.3 Asia Pacific
9.3.1 China
9.3.1.1 Market Drivers
9.3.1.2 Historical and Current Market Trends (2018-2023)
9.3.1.3 Market Breakup by Therapeutic Class
9.3.1.4 Market Breakup by Application
9.3.1.5 Market Breakup by Distribution Channel
9.3.1.6 Key Players
9.3.1.7 Market Forecast (2024-2032)
9.3.2 Japan
9.3.2.1 Market Drivers
9.3.2.2 Historical and Current Market Trends (2018-2023)
9.3.2.3 Market Breakup by Therapeutic Class
9.3.2.4 Market Breakup by Application
9.3.2.5 Market Breakup by Distribution Channel
9.3.2.6 Key Players
9.3.2.7 Market Forecast (2024-2032)
9.3.3 India
9.3.3.1 Market Drivers
9.3.3.2 Historical and Current Market Trends (2018-2023)
9.3.3.3 Market Breakup by Therapeutic Class
9.3.3.4 Market Breakup by Application
9.3.3.5 Market Breakup by Distribution Channel
9.3.3.6 Key Players
9.3.3.7 Market Forecast (2024-2032)
9.3.4 South Korea
9.3.4.1 Market Drivers
9.3.4.2 Historical and Current Market Trends (2018-2023)
9.3.4.3 Market Breakup by Therapeutic Class
9.3.4.4 Market Breakup by Application
9.3.4.5 Market Breakup by Distribution Channel
9.3.4.6 Key Players
9.3.4.7 Market Forecast (2024-2032)
9.3.5 Australia
9.3.5.1 Market Drivers
9.3.5.2 Historical and Current Market Trends (2018-2023)
9.3.5.3 Market Breakup by Therapeutic Class
9.3.5.4 Market Breakup by Application
9.3.5.5 Market Breakup by Distribution Channel
9.3.5.6 Key Players
9.3.5.7 Market Forecast (2024-2032)
9.3.6 Indonesia
9.3.6.1 Market Drivers
9.3.6.2 Historical and Current Market Trends (2018-2023)
9.3.6.3 Market Breakup by Therapeutic Class
9.3.6.4 Market Breakup by Application
9.3.6.5 Market Breakup by Distribution Channel
9.3.6.6 Key Players
9.3.6.7 Market Forecast (2024-2032)
9.3.7 Others
9.3.7.1 Historical and Current Market Trends (2018-2023)
9.3.7.2 Market Forecast (2024-2032)
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Drivers
9.4.1.2 Historical and Current Market Trends (2018-2023)
9.4.1.3 Market Breakup by Therapeutic Class
9.4.1.4 Market Breakup by Application
9.4.1.5 Market Breakup by Distribution Channel
9.4.1.6 Key Players
9.4.1.7 Market Forecast (2024-2032)
9.4.2 Mexico
9.4.2.1 Market Drivers
9.4.2.2 Historical and Current Market Trends (2018-2023)
9.4.2.3 Market Breakup by Therapeutic Class
9.4.2.4 Market Breakup by Application
9.4.2.5 Market Breakup by Distribution Channel
9.4.2.6 Key Players
9.4.2.7 Market Forecast (2024-2032)
9.4.3 Others
9.4.3.1 Historical and Current Market Trends (2018-2023)
9.4.3.2 Market Forecast (2024-2032)
9.5 Middle East and Africa
9.5.1 Market Drivers
9.5.2 Historical and Current Market Trends (2018-2023)
9.5.3 Market Breakup by Therapeutic Class
9.5.4 Market Breakup by Application
9.5.5 Market Breakup by Distribution Channel
9.5.6 Market Breakup by Country
9.5.7 Key Players
9.5.8 Market Forecast (2024-2032)
9.6 Attractive Investment Proposition by Region
10 Global Antipsychotic Drugs Market– Competitive Landscape
10.1 Overview
10.2 Market Structure
10.3 Market Share by Key Players
10.4 Market Player Positioning
10.5 Top Winning Strategies
10.6 Competitive Dashboard
10.7 Company Evaluation Quadrant
11 Profiles of Key Players
11.1 AbbVie Inc.
11.1.1 Business Overview
11.1.2 Therapeutic Class Portfolio
11.1.3 Business Strategies
11.1.4 Financials
11.1.5 SWOT Analysis
11.1.6 Major News and Events
11.2 Alkermes plc
11.2.1 Business Overview
11.2.2 Therapeutic Class Portfolio
11.2.3 Business Strategies
11.2.4 Financials
11.2.5 SWOT Analysis
11.2.6 Major News and Events
11.3 Dr. Reddy’s Laboratories Ltd.
11.3.1 Business Overview
11.3.2 Therapeutic Class Portfolio
11.3.3 Business Strategies
11.3.4 Financials
11.3.5 SWOT Analysis
11.3.6 Major News and Events
11.4 Johnson & Johnson
11.4.1 Business Overview
11.4.2 Therapeutic Class Portfolio
11.4.3 Business Strategies
11.4.4 Financials
11.4.5 SWOT Analysis
11.4.6 Major News and Events
11.5 Otsuka Pharmaceutical Co. Ltd.
11.5.1 Business Overview
11.5.2 Therapeutic Class Portfolio
11.5.3 Business Strategies
11.5.4 SWOT Analysis
11.5.5 Major News and Events
11.6 Viatris Inc.
11.6.1 Business Overview
11.6.2 Therapeutic Class Portfolio
11.6.3 Business Strategies
11.6.4 Financials
11.6.5 SWOT Analysis
11.6.6 Major News and Events
Please note that this is only a partial list of the key players, and the complete list is provided in the report.
12 Global Antipsychotic Drugs Market- Industry Analysis
12.1 Drivers, Restraints, and Opportunities
12.1.1 Overview
12.1.2 Drivers
12.1.3 Restraints
12.1.4 Opportunities
12.1.5 Impact Analysis
12.2 Porters Five Forces Analysis
12.2.1 Overview
12.2.2 Bargaining Power of Buyers
12.2.3 Bargaining Power of Suppliers
12.2.4 Degree of Competition
12.2.5 Threat of New Entrants
12.2.6 Threat of Substitutes
12.3 Value Chain Analysis
13 Strategic Recommendations
14 Appendix